News Column

StemCutis Taps Dr. Ike Lee as President and CEO, Elects Dermatologist Dr. Ronald Wheeland as Director

September 3, 2014

StemCutis has appointed stem cell entrepreneur Ike Lee, Ph.D., as President and CEO.

In its release, StemCutis said that in this role, he will explore breakthrough applications in stem cell therapies and drive global commercialization. In addition, former President of the American Academy of Dermatology Dr. Ronald Wheeland joins the company's Board of Directors, where he will share his expertise to advance worldwide dermatological treatments for skin diseases using stem cell therapies.

"StemCutis is privileged to engage the talents of Drs. Ike Lee and Ronald Wheeland, who will advance efforts to develop and commercialize stem cell therapies to heal compromised skin, as well as OTC products to improve skin appearance," said Nikolai Tankovich, M.D., Ph.D., StemCutis' Chairman of the Board and Stemedica's President and Chief Medical Officer.

Dr. Lee, a 16-year biotechnology veteran, earned his Ph.D. in molecular biology from the University of Georgia and spent four years as an Instructor at the Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital. Leveraging his research and experiences at Harvard, he founded Anterogen, one of the first successful stem cell therapy companies in Korea. Before joining StemCutis, he served as Co-founder and CEO of Alopax Bio- Consulting.

"StemCutis is the first company I've seen that addresses the market need for dermatology and skin care therapies that treat underlying problems rather than just symptoms," said Dr. Lee. "I am excited to join this effort to commercialize stem cell therapies that regenerate the skin's physiological processes and biological structures."

Dr. Wheeland, a 40-year dermatology expert and former president of the American Academy of Dermatology, the American Society for Dermatologic Surgery and the American Society for Laser Medicine and Surgery, earned his M.D. from the University of Arizona College of Medicine. He is the former Section Chief at the University of Arizona College of Medicine's Dermatology Division, and has also served as Professor and Chairman of the Department of Dermatology at UC Davis and the University of New Mexico.

"StemCutis has a unique opportunity to advance stem cell therapies for dermatology applications," said Ronald Wheeland, M.D., StemCutis' Board Member. "I'm privileged to join the stellar board of directors StemCutis has assembled, and I look forward to sharing my four decades of dermatology expertise to help commercialize the company's stem cell therapies."

More Information and Complete Details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Health & Beauty Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters